ATRA | Jotup

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, March 31, 2023

Oncology, Health, General Health, Research, Science, Biotechnology, ATRA, Northwest Biotherapeutics, Cancer, Employment, Epstein–Barr virus, Patient, EBV, Compensated emancipation, Pharmaceutical industry, Thermoplastic

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 93,950 restricted stock units of Atara’s common stock to three newly hired employees.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 3, 2023, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, March 3, 2023

Oncology, Health, Genetics, Research, Science, Biotechnology, Cancer, Epstein–Barr virus, EBV, Compensated emancipation, Employment, Northwest Biotherapeutics, Patient, ATRA, Pharmaceutical industry, Thermoplastic

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 62,350 restricted stock units of Atara’s common stock to six newly hired employees.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of March 1, 2023, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference

Retrieved on:

Wednesday, March 1, 2023

Biotechnology, Pharmaceutical, Health, Oncology, Northwest Biotherapeutics, Cancer, Webcast, PST, ATRA, Patient, EBV, EST, Conference, Epstein–Barr virus, Pharmaceutical industry, Broadcasting

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 11:10 a.m. PST / 2:10 p.m. EST.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Retrieved on:

Tuesday, February 21, 2023

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Conference, PST, Cancer, EST, ATRA, Webcast, Epstein–Barr virus, Northwest Biotherapeutics, EBV, Patient, Pharmaceutical industry, Broadcasting

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
A live webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com .
An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

Retrieved on:

Wednesday, February 8, 2023

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023.
“Following the landmark approval of EbvalloTM in Europe, we had productive discussions with the FDA about their requirements for a tab-cel BLA.
We welcome the opportunity to further discuss the topic of comparability that may advance our progress towards a BLA submission,” said Pascal Touchon, President and Chief Executive Officer of Atara.
Mr. Hyllengren will also serve as the Company’s Principal Financial Officer and Principal Accounting Officer
Mr. Hyllengren joined Atara in 2018 as Vice President, Financial Planning and Analysis and added the role of Head of Investor Relations in April 2020.

Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

Retrieved on:

Wednesday, February 8, 2023

Key Points:

From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
Pierre Fabre is planning to launch EBVALLO™ in the first European countries during quarter one of 2023.
The EC marketing authorization is based on results from the pivotal Phase 3 ALLELE study and additional supportive studies.
Atara retains full rights to EBVALLO™ in other major markets, including North America, Asia Pacific, and Latin America.

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

Retrieved on:

Monday, February 6, 2023

Biotechnology, Health, Oncology, ATRA, EBV, Northwest Biotherapeutics, Epstein–Barr virus, Patient, Cancer, Vaccine, Pharmaceutical industry

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023.

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, February 3, 2023

Oncology, Health, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, ATRA, EBV, Northwest Biotherapeutics, Employment, Epstein–Barr virus, Compensated emancipation, Patient, Cancer, Pharmaceutical industry

Key Points:

These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of February 1, 2023, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
The stock options have a ten-year term and an exercise price of $5.13, equal to the per share closing price of Atara’s common stock as reported on February 1, 2023.

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, January 13, 2023

Biotechnology, Health, Oncology, Other Health, Epstein–Barr virus, ATRA, Degenerative disease, Protalix BioTherapeutics, EBV, Financial compensation, Patient, Employment, Cancer, Pharmaceutical industry, Animal

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired employee.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of January 3, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
The stock options have a ten-year term and an exercise price of $3.28, equal to the per share closing price of Atara’s common stock as reported on January 3, 2022.

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on:

Wednesday, January 4, 2023

Biotechnology, Health, Genetics, Clinical Trials, Oncology, Northwest Biotherapeutics, Cancer, Patient, ATRA, Conference, Epstein–Barr virus, Degenerative disease, EBV, Webcast, Pharmaceutical industry, Broadcasting

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com .
An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.